Anixa Biosciences Inc (ANIX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 10-31. Amounts in USD.

Revenue TTM

0 5M 10M 15M Q2 '11: 473.2K Q3 '11: 865.5K Q4 '11: 1M Q1 '12: 1.4M Q2 '12: 1.6M Q3 '12: 1.4M Q4 '12: 947.1K Q1 '13: 500K Q2 '13: 251.9K Q3 '13: 2.5K Q4 '13: 388.9K Q1 '15: 12.8M Q2 '15: 11.7M Q3 '15: 10.6M Q4 '15: 9.3M Q2 '18: 1.1M Q3 '18: 1.1M Q4 '18: 1.1M Q1 '19: 1.1M Q2 '19: 612.5K Q3 '19: 250K Q4 '19: 250K Q4 '21: 512K Q1 '22: 512K Q2 '22: 512K Q4 '23: 210K Q3 '11 Q3 '12 Q3 '13 Q3 '15 Q4 '18 Q4 '19 Q4 '23

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-21M -14M -7M 0 7M 14M 21M Q2 '11: -5.2M Q3 '11: -5.1M Q4 '11: -5M Q1 '12: -4.4M Q2 '12: -4M Q3 '12: -3.4M Q4 '12: -4.1M Q1 '13: -5.3M Q2 '13: -6.3M Q3 '13: -7.9M Q4 '13: -7.9M Q1 '14: -7.8M Q2 '14: -7.3M Q3 '14: -5.3M Q4 '14: -5M Q1 '15: 777.4K Q2 '15: -565 Q3 '15: -1.3M Q4 '15: -944.8K Q1 '16: -6.3M Q2 '16: -5.3M Q3 '16: -4.8M Q4 '16: -4.5M Q1 '17: -4.4M Q2 '17: -4.5M Q3 '17: -5.3M Q4 '17: -6.1M Q1 '18: -6.6M Q2 '18: -6.7M Q3 '18: -10.6M Q4 '18: -14.3M Q1 '19: -17.4M Q2 '19: -18.6M Q3 '19: -15.2M Q4 '19: -11.9M Q1 '20: -9.5M Q2 '20: -9.6M Q3 '20: -9.9M Q4 '20: -10M Q1 '21: -9.6M Q2 '21: -9.3M Q3 '21: -11.3M Q4 '21: -13.1M Q1 '22: -14.8M Q2 '22: -15.9M Q3 '22: -14.3M Q4 '22: -13.9M Q1 '23: -12.6M Q2 '23: -11.5M Q3 '23: -11.6M Q4 '23: -11M Q1 '24: -12.1M Q2 '24: -13M Q3 '24: -13.7M Q4 '24: -13.8M Q1 '25: -13.6M Q2 '25: -13.1M Q3 '25: -12M Q4 '25: -11.7M Q1 '26: -11M Q2 '26: -10.7M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-21M -14M -7M 0 7M 14M 21M Q2 '11: -5.2M Q3 '11: -5.7M Q4 '11: -7.4M Q1 '12: -6.7M Q2 '12: -6.3M Q3 '12: -5.2M Q4 '12: -4.3M Q1 '13: -5.5M Q2 '13: -7.1M Q3 '13: -9M Q4 '13: -10.1M Q1 '14: -11.6M Q2 '14: -12.4M Q3 '14: -9.4M Q4 '14: -9.6M Q1 '15: -2.2M Q2 '15: -1.2M Q3 '15: -3.2M Q4 '15: -1.4M Q1 '16: -6.7M Q2 '16: -5.8M Q3 '16: -5.3M Q4 '16: -5M Q1 '17: -7M Q2 '17: -5.6M Q3 '17: -6.3M Q4 '17: -7M Q1 '18: -5.3M Q2 '18: -6.8M Q3 '18: -10.5M Q4 '18: -14M Q1 '19: -17.1M Q2 '19: -18.3M Q3 '19: -15M Q4 '19: -11.8M Q1 '20: -9.4M Q2 '20: -9.5M Q3 '20: -9.9M Q4 '20: -10M Q1 '21: -9.6M Q2 '21: -9.4M Q3 '21: -11.2M Q4 '21: -13M Q1 '22: -14.6M Q2 '22: -15.7M Q3 '22: -14.1M Q4 '22: -13.6M Q1 '23: -12.1M Q2 '23: -10.8M Q3 '23: -10.6M Q4 '23: -9.8M Q1 '24: -10.7M Q2 '24: -11.6M Q3 '24: -12.4M Q4 '24: -12.6M Q1 '25: -12.5M Q2 '25: -12.1M Q3 '25: -11.1M Q4 '25: -10.9M Q1 '26: -10.3M Q2 '26: -10M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-9M -6M -3M 0 3M 6M 9M Q3 '11: -520.7K Q4 '11: -716K Q1 '12: -763.6K Q2 '12: -930.1K Q3 '12: -2.9M Q4 '12: -3.1M Q1 '13: -3.4M Q2 '13: -3.4M Q3 '13: -3.6M Q4 '13: -3.2M Q1 '14: -3.5M Q2 '14: -3.1M Q3 '14: -2.6M Q4 '14: -2.4M Q1 '15: 3.4M Q2 '15: 2.2M Q3 '15: 1.8M Q4 '15: 1.4M Q1 '16: -3.8M Q2 '16: -3.4M Q3 '16: -3.5M Q4 '16: -3.4M Q1 '17: -3.6M Q2 '17: -3.3M Q3 '17: -3.7M Q4 '17: -3.8M Q1 '18: -4.4M Q2 '18: -4.1M Q3 '18: -4M Q4 '18: -4.3M Q1 '19: -4.3M Q2 '19: -5M Q3 '19: -4.4M Q4 '19: -4.7M Q1 '20: -5.3M Q2 '20: -5.4M Q3 '20: -6.1M Q4 '20: -6.2M Q1 '21: -5.4M Q2 '21: -5.1M Q3 '21: -5.3M Q4 '21: -4.9M Q1 '22: -5M Q2 '22: -6M Q3 '22: -5.9M Q4 '22: -6.5M Q1 '23: -7.3M Q2 '23: -5.8M Q3 '23: -5.8M Q4 '23: -6.2M Q1 '24: -6.5M Q2 '24: -7.2M Q3 '24: -8.4M Q4 '24: -7.3M Q1 '25: -7.9M Q2 '25: -8M Q3 '25: -6.8M Q4 '25: -7.2M Q1 '26: -6.9M Q2 '26: -7.1M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '11: -725K Q1 '12: -767.2K Q2 '12: -932.3K Q3 '12: -2.9M Q4 '12: -3.1M Q1 '13: -3.4M Q2 '13: -3.4M Q3 '13: -3.6M Q4 '15: 1.3M Q1 '16: -3.9M Q2 '16: -3.5M Q3 '16: -3.6M Q4 '16: -3.5M Q1 '17: -3.6M Q2 '17: -3.3M Q3 '17: -3.8M Q4 '17: -3.8M Q1 '18: -4.4M Q2 '18: -4.1M Q3 '18: -4M Q4 '18: -4.3M Q2 '20: -5.5M Q3 '20: -6.1M Q4 '20: -6.2M Q2 '12 Q1 '13 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q4 '18 Q4 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q1 '14: 210.2M Q3 '14: 10.6M Q1 '15: 9.3M Q3 '15: 8.8M Q1 '16: 8.7M Q2 '16: 8.7M Q2 '17: 9.7M Q2 '18: 16.7M Q1 '21: 25.2M Q2 '21: 28.7M Q3 '21: 30.5K Q1 '22: 30.1K Q2 '22: 30.2K Q3 '22: 30.5K Q1 '23: 30.9K Q2 '23: 30.9K Q3 '23: 31K Q1 '24: 31.4M Q2 '24: 31.9M Q3 '24: 32.1M Q1 '25: 32.2M Q2 '25: 32.2M Q3 '25: 32.5M Q1 '26: 33.2M Q2 '26: 33.6M Q1 '14 Q1 '16 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q2 '11: -0.03 Q3 '11: -0.03 Q4 '11: -0.05 Q1 '12: -0.04 Q2 '12: -0.03 Q3 '12: -0.02 Q4 '12: -0.01 Q1 '13: -0.02 Q2 '13: -0.03 Q3 '13: -0.04 Q4 '13: -0.04 Q1 '14: -0.05 Q2 '14: -0.05 Q3 '14: 0.00 Q4 '14: -0.34 Q1 '15: 0.09 Q2 '15: -0.15 Q3 '15: -0.37 Q4 '15: -16.01 Q1 '16: -16.60 Q2 '16: -16.50 Q3 '16: -16.45 Q4 '16: -0.58 Q1 '17: -0.81 Q2 '17: -0.64 Q3 '17: -0.63 Q4 '17: -0.62 Q1 '18: -0.32 Q2 '18: -0.42 Q3 '18: -0.60 Q4 '18: -0.78 Q1 '19: -0.92 Q2 '19: -0.97 Q3 '19: -0.78 Q4 '19: -0.59 Q1 '20: -0.47 Q2 '20: -0.46 Q3 '20: -0.46 Q4 '20: -0.45 Q1 '21: -0.41 Q2 '21: -0.37 Q3 '24: -0.39 Q4 '24: -0.39 Q1 '25: -0.39 Q2 '25: -0.38 Q3 '25: -0.35 Q4 '25: -0.35 Q1 '26: -0.33 Q2 '26: -0.31 Q4 '12 Q3 '14 Q2 '16 Q1 '18 Q4 '19 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.